Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Norgine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Product Name : PER977
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2021
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Norgine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clot...
Product Name : PER977
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The published preclinical data demonstrate that ciraparantag has several key attributes including its ability to reverse the anticoagulant effect of apixaban, rivaroxaban, edoxaban, dabigatran, and LMWH.
Product Name : PER977
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Norgine
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontro...
Product Name : PER977
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
July 23, 2020
Lead Product(s) : Ciraparantag
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Norgine
Deal Size : $290.0 million
Deal Type : Licensing Agreement